Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R de Wit

Showing results (91-100 of 147) with videos related to

Pageof 15
Sort By:
European Journal of Cancer (Oxford, England : 1990)|January 30, 2004
The oral NK(1) antagonist, aprepitant, given with standard antiemetics provides protection against nausea and vomiting over multiple cycles of cisplatin-based chemotherapy: a combined analysis of two randomised, placebo-controlled phase III clinical trialsR de Wit, J Herrstedt, B Rapoport, et al.
British Journal of Cancer|July 29, 1999
A phase I/II study of combined weekly systemic cisplatin and locoregional hyperthermia in patients with previously irradiated recurrent carcinoma of the uterine cervixR de Wit, J van der Zee, M E van der Burg, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 24, 1999
Empirical comparison of commonly used measures to evaluate pain treatment in cancer patients with chronic painR de Wit, F van Dam, H H Abu-Saad, et al.
European Journal of Cancer (Oxford, England : 1990)|January 31, 2002
Retreatment with dose-dense weekly cisplatin after previous cisplatin chemotherapy is not complicated by significant neuro-toxicityM J van den Bent, W L J van Putten, P H E Hilkens, et al.
British Journal of Cancer|July 4, 1998
Initial high anti-emetic efficacy of granisetron with dexamethasone is not maintained over repeated cyclesR de Wit, H van den Berg, J Burghouts, et al.
European Journal of Cancer (Oxford, England : 1990)|October 12, 2002
Dose-dense cisplatin/paclitaxel. a well-tolerated and highly effective chemotherapeutic regimen in patients with advanced ovarian cancerF E de Jongh, R de Wit, J Verweij, et al.
Journal of Pharmaceutical and Biomedical Analysis|September 7, 2007
Pitfalls of the application of microdialysis in clinical oncology: controversial findings with docetaxelW J Loos, W C Zamboni, F K Engels, et al.
British Journal of Cancer|February 22, 2002
Weekly cisplatin and daily oral etoposide is highly effective in platinum pretreated ovarian cancerM E L van der Burg, R de Wit, W L J van Putten, et al.
BMC Cancer|June 13, 2023
The CHASIT study: sequential chemo-immunotherapy in patients with locally advanced urothelial cancer - a non-randomized phase II clinical trialV C Rutten, Y Salhi, G J Robbrecht, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 5, 2001
Body-surface area-based dosing does not increase accuracy of predicting cisplatin exposureF E de Jongh, J Verweij, W J Loos, et al.
Pageof 15

Showing results (91-100 of 147) with videos related to

Sort By:
Pageof 15
European Journal of Cancer (Oxford, England : 1990)|January 30, 2004
The oral NK(1) antagonist, aprepitant, given with standard antiemetics provides protection against nausea and vomiting over multiple cycles of cisplatin-based chemotherapy: a combined analysis of two randomised, placebo-controlled phase III clinical trialsR de Wit, J Herrstedt, B Rapoport, et al.
British Journal of Cancer|July 29, 1999
A phase I/II study of combined weekly systemic cisplatin and locoregional hyperthermia in patients with previously irradiated recurrent carcinoma of the uterine cervixR de Wit, J van der Zee, M E van der Burg, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 24, 1999
Empirical comparison of commonly used measures to evaluate pain treatment in cancer patients with chronic painR de Wit, F van Dam, H H Abu-Saad, et al.
European Journal of Cancer (Oxford, England : 1990)|January 31, 2002
Retreatment with dose-dense weekly cisplatin after previous cisplatin chemotherapy is not complicated by significant neuro-toxicityM J van den Bent, W L J van Putten, P H E Hilkens, et al.
British Journal of Cancer|July 4, 1998
Initial high anti-emetic efficacy of granisetron with dexamethasone is not maintained over repeated cyclesR de Wit, H van den Berg, J Burghouts, et al.
European Journal of Cancer (Oxford, England : 1990)|October 12, 2002
Dose-dense cisplatin/paclitaxel. a well-tolerated and highly effective chemotherapeutic regimen in patients with advanced ovarian cancerF E de Jongh, R de Wit, J Verweij, et al.
Journal of Pharmaceutical and Biomedical Analysis|September 7, 2007
Pitfalls of the application of microdialysis in clinical oncology: controversial findings with docetaxelW J Loos, W C Zamboni, F K Engels, et al.
British Journal of Cancer|February 22, 2002
Weekly cisplatin and daily oral etoposide is highly effective in platinum pretreated ovarian cancerM E L van der Burg, R de Wit, W L J van Putten, et al.
BMC Cancer|June 13, 2023
The CHASIT study: sequential chemo-immunotherapy in patients with locally advanced urothelial cancer - a non-randomized phase II clinical trialV C Rutten, Y Salhi, G J Robbrecht, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 5, 2001
Body-surface area-based dosing does not increase accuracy of predicting cisplatin exposureF E de Jongh, J Verweij, W J Loos, et al.
Pageof 15